Abstract
Recently, Pahor et al. (1) presented a meta-analysis based on four studies assessing whether ACE inhibitors are superior to alternative agents for the prevention of cardiovascular events in patients with hypertension and type 2 diabetes. The four eligible trials were as follows: 1 ) the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET), 2 ) the Appropriate Blood Pressure Control in Diabetes Trial (ABCD), 3 ) the Captopril Prevention Project (CAPPP), and 4 ) the U.K. Prospective Diabetes Study (UKPDS) (2,3,4,5). FACET's study lasted only 2.8 years, whereas the other studies lasted 5, 6.1, and 8.4 years, respectively. All of the trials were blind except for FACET. The primary end points of FACET were serum lipids and glucose metabolism, whereas the primary …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
